REG - Trellus Health PLC - Appointment of Chief Financial Officer

Trellus HealthAnnouncement

12/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0763Ma&default-theme=true

RNS Number : 0763M  Trellus Health PLC  12 September 2023

Trellus Health plc

("Trellus Health" or the "Company")

 

Appointment of Chief Financial Officer

 

LONDON, U.K. AND NEW YORK, U.S. (12 September 2023). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated and clinically
proven personalized resilience-driven self-management solution for chronic
health conditions at their intersection with mental health, announces the
appointment of Joy Bessenger as Chief Financial Officer in a non-Board
capacity, effective from 18 September. Joy's appointment follows the
appointment of Steve Young, Interim Chief Financial Officer, as full-time CFO
of EKF Diagnostics Holdings plc. Joy has been working as a consultant for
Trellus Health since late July as part of an orderly handover from Steve.

 

Joy has worked for over 20 years with both privately and publicly held life
sciences and healthcare companies, with significant experience across finance,
operations, corporate strategy and development, compliance and governance and
strategic communications.

 

Her most recent full-time role was at IMV, Inc., a clinical-stage, dual-listed
(NASDAQ/TSX) biotechnology company, where she served as Senior Vice President,
Corporate Strategy and Investor Relations. There, she took responsibility for
a large portion of the CFO role, working closely with the CEO to develop a new
capital markets and corporate strategy, helping to secure a $25m debt facility
and engaging with current and potential partners, as well as institutional
investors.

 

From 2017-2019, Joy served as Senior Vice President, Finance and Strategy of
IN8bio, a then privately-held biotechnology company, where she helped raise a
$10 million Series A financing, engaging with new and existing investors.
Prior to this, Joy was the Co-Founder and Chief Financial Officer of 3D
Forensic, Inc., a privately held forensic animation company, where she raised
seed investment from angel investors, and developed a five-year strategic
plan.

 

Dr. Marla Dubinsky, CEO and Co-Founder of Trellus Health, said: "I am
delighted to welcome Joy to the Trellus Health team as our new CFO. I believe
her wealth of experience in life sciences and healthcare companies will be of
great value to Trellus Health as we look to further execute our commercial
strategy and secure additional partnerships, having evolved our delivery model
and aligned our expenditure to lengthen the cash runway into at least 2025. On
behalf of the Board, I would also like to thank Steve Young for his
contribution to the Company during his time as Interim CFO, and wish him the
best in his new role."

 

Joy Bessenger, incoming CFO of Trellus Health, said: "I believe the Trellus
Elevate™ program has the potential to change the lives of people with
chronic illnesses. I am excited to join Trellus Health at this stage in its
journey and help deliver its whole-person healthcare approach to as many
people as possible."

 

 

For further information please contact:

 

 Trellus Health plc                                                          https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                      Via Walbrook PR
 Dr. Daniel Mahony Chairman

 Singer Capital Markets (Nominated Adviser and Broker)                       Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / 07748 651 727 / 07867 984 082

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience-focused digital health
company targeting the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience that
empowers individuals to master their health and results in relieving disease
burden, building self-management skills and promoting positive health
behaviours that improves outcomes and enables thriving in the face of a
chronic condition.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both experts at treating and healing both the physical
and emotional impacts of IBD and IBS and have been innovators for whole person
healthcare for a combined 50 years.

 

The Company was initially focused on inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common
emotional and mental health struggles often experienced by individuals
suffering from a variety of chronic conditions, Trellus Health considers its
approach to have potential utility and demand across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and
learnings on resilience from clinical research and practice conducted at the
Mount Sinai IBD Center for more than five years. This proprietary,
resilience-driven methodology has been scientifically validated to demonstrate
meaningful improvements in patient outcomes, 71% reduction in Emergency
Department (A&E) visits, and 94% reduction in unplanned hospitalisations,
which the directors of the Company believe indicates the potential for
significant cost savings for healthcare payers. Patients with IBD managed with
the proprietary resilience methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12 months
following starting the program which is a major indicator of improved health
outcomes(1).

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABRGDCRBBDGXB